| HOME >> BIOLOGY >> TECHNOLOGY |
NEW BRUNSWICK, N.J., March 25 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. (the "Company") (Amex: SNT), today announced receipt of a notice from the American Stock Exchange ("AMEX") stating that the Company has resolved the continued listing deficiencies referenced in the AMEX's letters dated June 15, 2007 and October 24, 2007. The conclusion is based upon a review of publicly available information pertaining to the Company, including its Securities and Exchange Commission filings.
Senesco is now subject to the provisions of Section 1009(h) which states that if the Company, within 12 months of March 1, 2008, is again determined to be below the continued listing standards, the AMEX staff then may take appropriate action, which, depending upon the circumstances, may include providing the Company with an opportunity to submit a plan to the AMEX advising the AMEX of action the Company has taken, or will take, that would bring it into compliance with the continued listing standards, or the AMEX may immediately initiate delisting proceedings.
About Senesco Technologies, Inc.
Senesco Technologies, Inc. is a U.S. biotechnology company,
headquartered in New Brunswick, NJ. Senesco has initiated preclinical
research to trigger or delay cell death in mammals (apoptosis) to determine
if the technology is applicable in human medicine. Accelerating apoptosis
may have applications to development of cancer treatments. Delaying
apoptosis may have applications to certain inflammatory and ischemic
diseases. Senesco takes its name from the scientific term for the aging of
plant cells: senescence. Delaying cell breakdown in plants extends
freshness after harvesting, while increasing crop yields, plant size and
resistance to environm
'/>"/>
| SOURCE Senesco Technologies, Inc. Copyright©2008 PR Newswire. All rights reserved |